Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma
- PMID: 8984917
- PMCID: PMC1511750
- DOI: 10.1136/adc.75.4.314
Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma
Abstract
Serum eosinophilic cationic protein (ECP) and soluble low affinity receptor for IgE (Fc epsilon RII/sCD23) concentrations were measured in relation to symptom-medication scores, pulmonary function, and total IgE levels in 27 chronic allergic asthmatic children (17 boys, 10 girls), mean age 10.8 years, before and at the end of a three month inhaled corticosteroid (budesonide) treatment period. Serum ECP and sCD23 concentrations were also measured in age matched non-asthmatic controls with allergic rhinitis. All asthma patients had significantly higher serum ECP and sCD23 than the controls, whereas the mean serum IgE was not different. No correlation between total IgE concentrations and serum sCD23 could be detected in either group. At the end of the treatment period, symptom-medication scores and pulmonary function improved. Serum ECP and sCD23 concentrations were reduced; however, total IgE values did not change significantly. A significant relation was found between the improvement of symptom-medication scores and fall in both sCD23 and ECP concentrations. Although there was a significant correlation of pulmonary function values with serum ECP, no such relation was observed for sCD23. It appears that serum sCD23 and ECP concentrations could be good disease markers, particularly in asthma. Monitoring of serum inflammation markers, especially ECP, may be useful in the follow up of asthmatic children on anti-inflammatory treatment.
Similar articles
-
Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season.Allergy Asthma Proc. 1999 Mar-Apr;20(2):119-25. doi: 10.2500/108854199778612590. Allergy Asthma Proc. 1999. PMID: 10209690
-
Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking.Am J Respir Crit Care Med. 1996 May;153(5):1519-29. doi: 10.1164/ajrccm.153.5.8630596. Am J Respir Crit Care Med. 1996. PMID: 8630596 Clinical Trial.
-
Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood.Pediatr Allergy Immunol. 2000 May;11(2):87-94. doi: 10.1111/j.1399-3038.2000.00079.x. Pediatr Allergy Immunol. 2000. PMID: 10893010 Clinical Trial.
-
Serum measurement of eosinophil cationic protein in the management of asthma.Curr Opin Pulm Med. 1999 Mar;5(2):111-7. doi: 10.1097/00063198-199903000-00006. Curr Opin Pulm Med. 1999. PMID: 10813261 Review.
-
Clinical application of eosinophilic cationic protein in asthma.Allergy Proc. 1995 Mar-Apr;16(2):59-62. doi: 10.2500/108854195778771426. Allergy Proc. 1995. PMID: 7797059 Review.
Cited by
-
Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.Drugs. 2000 Nov;60(5):1141-78. doi: 10.2165/00003495-200060050-00010. Drugs. 2000. PMID: 11129126 Review.
-
Cough, airway inflammation, and mild asthma exacerbation.Arch Dis Child. 2002 Apr;86(4):270-5. doi: 10.1136/adc.86.4.270. Arch Dis Child. 2002. PMID: 11919102 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical